| MeSH term | MeSH ID | Detail |
|---|---|---|
| Diabetes Mellitus, Experimental | D003921 | 85 associated lipids |
| Encephalitis | D004660 | 15 associated lipids |
| Epilepsy | D004827 | 35 associated lipids |
| Fatty Liver, Alcoholic | D005235 | 11 associated lipids |
| Fragile X Syndrome | D005600 | 5 associated lipids |
| Glioma | D005910 | 112 associated lipids |
| Hepatic Encephalopathy | D006501 | 9 associated lipids |
| Hyperalgesia | D006930 | 42 associated lipids |
| Hyperinsulinism | D006946 | 27 associated lipids |
| Hyperkinesis | D006948 | 11 associated lipids |
2-arachidonoylglycerol
2-arachidonoylglycerol is a lipid of Glycerolipids (GL) class. 2-arachidonoylglycerol is associated with abnormalities such as Atherosclerosis, Heart Diseases, Inflammatory disorder, Colitis and Peripheral Neuropathy. The involved functions are known as Immunoreactivity, inhibitors, Stimulus, Esthesia and Signal Transduction. 2-arachidonoylglycerol often locates in Back, Presynaptic Terminals, Brain region, Blood and Body tissue. The associated genes with 2-arachidonoylglycerol are ADRBK1 gene, Homologous Gene, MGLL gene, PLA2G4A gene and peptide V. The related lipids are oleoylethanolamide, Lipopolysaccharides, Promega, stearic acid and 1-stearoyl-2-arachidonoylglycerol. The related experimental models are Knock-out.
Cross Reference
Introduction
To understand associated biological information of 2-arachidonoylglycerol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with 2-arachidonoylglycerol?
2-arachidonoylglycerol is suspected in Atherosclerosis, Heart Diseases, Sweet's Syndrome, Colitis, Dehydration, Diabetes and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 2-arachidonoylglycerol
PubChem Associated disorders and diseases
What pathways are associated with 2-arachidonoylglycerol
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with 2-arachidonoylglycerol?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with 2-arachidonoylglycerol?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with 2-arachidonoylglycerol?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with 2-arachidonoylglycerol?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with 2-arachidonoylglycerol?
Knock-out
Knock-out are used in the study 'Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.' (Walentiny DM et al., 2015), Knock-out are used in the study 'Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12).' (Navia-Paldanius D et al., 2012) and Knock-out are used in the study 'Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid Action.' (Viader A et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with 2-arachidonoylglycerol
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Fowler CJ et al. | Fatty acid amide hydrolase: biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol, palmitoylethanolamide, and oleamide. | 2001 | Biochem. Pharmacol. | pmid:11585048 |
| Baker D et al. | Endocannabinoids control spasticity in a multiple sclerosis model. | 2001 | FASEB J. | pmid:11156943 |
| MacCarrone M et al. | Human platelets bind and degrade 2-arachidonoylglycerol, which activates these cells through a cannabinoid receptor. | 2001 | Eur. J. Biochem. | pmid:11168423 |
| Al-Hayani A et al. | The endogenous cannabinoid anandamide activates vanilloid receptors in the rat hippocampal slice. | 2001 | Neuropharmacology | pmid:11747904 |
| Kagota S et al. | 2-Arachidonoylglycerol, a candidate of endothelium-derived hyperpolarizing factor. | 2001 | Eur. J. Pharmacol. | pmid:11275004 |
| Wang Y et al. | Simultaneous measurement of anandamide and 2-arachidonoylglycerol by polymyxin B-selective adsorption and subsequent high-performance liquid chromatography analysis: increase in endogenous cannabinoids in the sera of patients with endotoxic shock. | 2001 | Anal. Biochem. | pmid:11412008 |
| Maccarrone M et al. | Gas chromatography-mass spectrometry analysis of endogenous cannabinoids in healthy and tumoral human brain and human cells in culture. | 2001 | J. Neurochem. | pmid:11208922 |
| Berdyshev EV et al. | Activation of PAF receptors results in enhanced synthesis of 2-arachidonoylglycerol (2-AG) in immune cells. | 2001 | FASEB J. | pmid:11641243 |
| Sugiura T and Waku K | 2-arachidonoylglycerol: a possible multifunctional lipid mediator in the nervous and immune systems. | 2000 | Ann. N. Y. Acad. Sci. | pmid:10818479 |
| Sugiura T et al. | Generation of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, in picrotoxinin-administered rat brain. | 2000 | Biochem. Biophys. Res. Commun. | pmid:10814517 |
| Basavarajappa BS et al. | Stimulation of cannabinoid receptor agonist 2-arachidonylglycerol by chronic ethanol and its modulation by specific neuromodulators in cerebellar granule neurons. | 2000 | Biochim. Biophys. Acta | pmid:11113634 |
| Pryor SR | Is platelet release of 2-arachidonoyl-glycerol a mediator of cognitive deficits? An endocannabinoid theory of schizophrenia and arousal. | 2000 | Med. Hypotheses | pmid:11090297 |
| Rhee MH et al. | Functional role of tryptophan residues in the fourth transmembrane domain of the CB(2) cannabinoid receptor. | 2000 | J. Neurochem. | pmid:11080201 |
| Kunos G et al. | Cardiovascular effects of endocannabinoids--the plot thickens. | 2000 | Prostaglandins Other Lipid Mediat. | pmid:10785543 |
| Maccarrone M et al. | Anandamide and 2-arachidonoylglycerol inhibit fatty acid amide hydrolase by activating the lipoxygenase pathway of the arachidonate cascade. | 2000 | Biochem. Biophys. Res. Commun. | pmid:11095952 |
| Howlett AC and Mukhopadhyay S | Cellular signal transduction by anandamide and 2-arachidonoylglycerol. | 2000 | Chem. Phys. Lipids | pmid:11106782 |
| Stefano GB et al. | 2-arachidonyl-glycerol stimulates nitric oxide release from human immune and vascular tissues and invertebrate immunocytes by cannabinoid receptor 1. | 2000 | Pharmacol. Res. | pmid:10987990 |
| Di Marzo V et al. | Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide. | 2000 | Eur. J. Pharmacol. | pmid:11040343 |
| Szallasi A and Di Marzo V | New perspectives on enigmatic vanilloid receptors. | 2000 | Trends Neurosci. | pmid:11006466 |
| Di Marzo V et al. | Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. | 2000 | FASEB J. | pmid:10877836 |